Joseph Chen

Joseph Chen

Pfizer Inc. - New York / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4398793
-
person_outline Joseph Chen's MOST POPULAR ARTICLES
1-) Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ...The Lancet Oncology 19 (12), 1654-1667, 20185582018
2-) Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ...The Lancet Oncology 18 (12), 1590-1599, 20175412017
3-) Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial resultsKC Goldsmith, JR Park, K Kayser, J Malvar, YY Chi, SG Groshen, ...Nature medicine 29 (5), 1092-1102, 2023372023
4-) Low endotoxin recovery in common biologics productsJ Chen, A VintherPDA Annual Meeting, Orlando, FL, 2013462013
5-) Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.KC Goldsmith, K Kayser, SG Groshen, M Chioda, HC Thurm, J Chen, ...Journal of Clinical Oncology 38 (15_suppl), 10504-10504, 2020322020